Citrate reduced gold nanoparticles lowered lipid content in differentiated 3T3-L1 adipocytes by altering the expression of adipogenic genes Authors: Anelisiwe Hyera, Jyoti Rajan Sharma, Adewale Oluwaseun Fadaka, Kwazikwakhe Bethuel Gabuza, Zanele Mganto-Khuselo, Abram Madimabe Madiehe, Mervin Meyer, Nicole Remaliah Samantha Sibuyi Published: 2026 ABSTRACT AbstractObesity and related metabolic disorders are increasing at alarming rates worldwide, posing a major public health challenge. Current anti-obesity therapies are limited by toxicity and adverse side effects, highlighting the need for alternative strategies. Nanotechnology offers a promising approach, with gold nanoparticles (AuNPs) attracting significant attention in biomedical applications due to their unique physicochemical properties and potential therapeutic effects. This study investigated the anti-lipogenic effects of citrate-capped AuNPs (cAuNPs) on differentiated 3T3-L1 adipocytes. The 14 nm cAuNPs were synthesized using the citrate reduction method and characterized using UV-vis spectroscopy, dynamic light scattering (DLS), and transmission electron microscopy (TEM). The effects of cAuNPs were evaluated on cell viability, lipid accumulation, and gene expression in 3T3-L1 cells and differentiated 3T3-L1 adipocytes. cAuNPs were non-cytotoxic to 3T3-L1 cells at concentrations up to 400 nM. Oil Red O (ORO) staining revealed a concentration-dependent reduction in lipid accumulation, with the maximal effect at 72 h. Gene expression analysis using RT2 PCR arrays identified 35 differentially expressed genes, with significant alterations in genes related to adipogenesis and lipid metabolism. Functional enrichment and protein–protein interaction (PPi) network analyses highlighted modulation of PPAR signalling and key hub genes involved in adipocyte function. These findings demonstrated that cAuNPs exert anti-adipogenic effects by altering molecular pathways associated with lipid storage, suggesting their potential as a nanotechnology-based strategy for obesity management. Future in vivo studies will be essential to assess their therapeutic efficacy and safety in order to advance AuNPs as innovative anti-obesity agents.Keywords: 3T3-L1 differentiated adipocytes, Anti-lipogenic effects, Gold nanoparticles, Nanotechnology, Obesity Introduction Obesity has become a global health crisis, affecting both developed and developing nations and posing significant public health challenges [1] . It is associated with serious metabolic diseases such as type 2 diabetes [2], cardiovascular diseases [3, 4], hypertension [3], dyslipidaemia [2], and some types of cancers [5], not limited to endometrial, breast, ovarian, prostate, liver, gallbladder, kidney, and colorectal cancers [6]. The socioeconomic burden imposed by these diseases is particularly pronounced in emerging economies like South Africa, where healthcare systems are already under strain [7]. Management of obesity presents significant challenges due to the complex nature of the disease and the limitations of current treatment strategies. Existing approaches, including lifestyle modifications, pharmacological interventions, and surgical procedures, often fall short in providing effective solutions for many patients [8]. The anti-obesity drugs that are commercially available, while potentially beneficial in the short term, often result in serious side effects with long-term use, limiting their efficacy and patient compliance [9]. These limitations, coupled with the increasing prevalence of obesity worldwide, underscore the urgent need for novel anti-obesity compounds that can offer more effective and sustainable treatment options with minimal adverse effects. The evolution of materials science has revolutionized biomedical applications, particularly through the development of nanomaterials [10]. While both organic and inorganic nanomaterials play a significant role in disease therapeutics, the inorganic nanomaterials (metal-based nanoparticles, MNPs) demonstrated several advantages due to their unique properties [11]. AuNPs possess unique physicochemical properties, including high surface-to-volume ratio, tunable size and shape, and ease of functionalization, making them ideal candidates for biomedical applications [12]. They are among the MNPs that were shown to have multiple bioactivities such as antimicrobial [13], antidiabetic [14], anticancer [15], lipid lowering [16], and anti-inflammatory activities [17]. Thus, AuNPs have emerged as a promising alternative treatment strategy for obesity. Their potential to modulate cellular processes and their ability to be targeted to specific tissues could offer new avenues for addressing the complex pathophysiology of obesity [18]. In a previous study, Wusu et al. demonstrated that 14 nm cAuNPs altered the expression of genes related to fatty acid and lipid metabolism in human colorectal adenocarcinoma (Caco-2) cells [19]. These findings suggested potential anti-lipogenic and anti-obesity effects of cAuNPs. Thus, the current study aimed to investigate the effects of cAuNPs on differentiated 3T3-L1 adipocytes, a widely used in vitro model for adipocytes. The 3T3-L1 cells differentiate from pre-adipocytes into mature adipocytes, accumulating lipids and expressing key adipogenic genes, providing an ideal system for studying the direct effects of cAuNPs on adipocyte biology and function [20, 21]. By examining the impact of cAuNPs on lipid accumulation, gene expression, and metabolic pathways in these cells, we aim to gain insights into their potential as novel therapeutic agents for obesity management. Materials and methods cAuNPs synthesis and characterization cAuNPs were synthesized as previously described [22]. Briefly, 1mM hydrogen tetrachloroaurate (Sigma, St Louis, USA) was added into boiling distilled water under continuous stirring at 650 rpm. Then, 1% (w/v) solution of sodium citrate (Sigma-Aldrich) was added into the boiling solution. The heat was turned off after the solution changed colour from pale yellow to ruby red and continued to stir for 60 min. Heating was discontinued once a visible colour change was observed, and the mixture was stirred for an additional 60 min at room temperature to ensure complete nanoparticle formation. The cAuNPs were washed three times with distilled water, followed by centrifugation at 14 000 rpm. Optical characterization was performed using UV-visible (UV-vis) spectrophotometry (POLARstar Omega plate reader, BMG Labtech, Offenburg, Germany) in the 400–800 nm range. Morphological analysis was conducted on a High-Resolution TEM (HRTEM; FEI Tecnai G2, Oregon, USA) operated at 200 kV, and particle core size distribution was determined by analysing TEM images with ImageJ software (National Institute of Health, Bethesda, Maryland, USA). Hydrodynamic size and colloidal stability were assessed using DLS (Malvern Nano-ZS90 Zeta- sizer, Worcestershire, UK). The cAuNPs concentration was estimated from UV-vis spectra using the Beer-Lambert law equation [23], and the inductively coupled plasma optical emission spectrometry (ICP-OES) on a Varian 710-ES ICP-OES (CA, USA) as previously described elsewhere [18]. Effect of cAuNPs on 3T3-L1 cells Preadipocyte differentiation The 3T3-L1 cells were purchased from the American Type Culture Collection (Manassas, Virginia, USA), and they were a gift from the Biomedical Research and Innovation Platform (SAMRC, Tygerberg, Cape Town). The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Lonza, Verviers, Belgium) supplemented with 10% foetal bovine serum (FBS; Gibco, Mannheim, Germany) and 1% penicillin-streptomycin cocktail (Lonza) in a 37 °C humidified incubator with 5% CO2. To differentiate 3T3-L1 pre-adipocytes into adipocytes, 3 × 104 cells/mL were seeded in a 96-well plate and incubated for 48 h. Then, the medium was replaced with MDI induction media, composed of DMEM containing 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich), 1 µM dexamethasone (Sigma-Aldrich), and 10 µg/mL insulin (Roche, Germany) for 48 h [24]. Cells were maintained in a DMEM with 10 µg/mL insulin for another 48 h, followed by DMEM/10% FBS until cells were fully differentiated into mature adipocytes by day 10. As a negative control to determine if there was no auto differentiation of the pre-adipocytes into adipocytes, 3T3-L1 pre-adipocytes (undifferentiated) followed the entire 10-day process in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin [25]. Cell viability analysis The 3T3-L1 cells (undifferentiated and differentiated) were prepared as described in 2.2.1. The culture medium was replaced every 2 days, and at day 10 with 100 µL of DMEM containing 0–400 nM cAuNPs for 24 to 72 h in three separate 96-well microplates. In the negative control cells, culture medium without treatments was added. Following respective incubation periods, the treatments were removed and replaced with 100 µL of 1:10 WST-1 cell proliferation reagent (Roche, Mannheim) prepared in DMEM, followed by incubation at 37 °C for 3 h. Additional wells containing the same range of cAuNPs concentrations without the WST-1 were used to determine if there was interference of the cAuNPs with the assay. Absorbance was recorded at 440 nm on a PolarSTAR Omega plate reader with background subtraction at 630 nm. The cell viability was expressed as percentage cell viability of treated samples relative to the negative control cells, multiplied by 100% [25]. ORO staining Lipid accumulation was assessed using ORO staining, a fat-soluble diazo dye that specifically stains neutral triglycerides and lipids by forming a red-coloured complex through hydrophobic interactions [26]. Undifferentiated and differentiated 3T3-L1 cells treated with 0–400 nM cAuNPs, were washed twice with 1x Dulbecco’s phosphate buffered saline (DPBS; Lonza) and then fixed with 10% neutral buffered formalin (Sigma-Aldrich) for 15 min at room temperature. After fixation, the cells were then incubated with 0.7% (v/v) ORO (Sigma-Aldrich) stain for 30 min at room temperature. The ORO stain was removed and rinsed three times with distilled water (dH2O). Images of the stained cells were observed and captured using an EVOS XL Core imaging System microscope (Invitrogen, USA). To quantify the lipid accumulation, the ORO stain was eluted with isopropanol and the absorbance was measured at 490 nm using a POLARstar Omega plate reader. The cells were then washed with dH2O and re-stained with 0.5% (v/v) crystal violet (CV; Sigma-Aldrich) solution extracted with 70% (v/v) ethanol for 5 min at room temperature. Following the removal of the CV dye, the cells were washed three times with 1x DPBS and the absorbance was measured at 570 nm using a POLARstar Omega plate reader. ORO absorption values were normalized against CV absorption values (ORO/CV) and expressed as the relative triglyceride content of the treated samples compared to control cells [25] . Adipogenesis RT2 PCR array analysis RNA extraction, reverse transcription, and qPCR Cells were seeded at 2 × 105 cells/mL in T25 cm2 culture flasks and differentiated into adipocytes as described previously. Thereafter, the cells were treated with 12.5 nM cAuNPs in DMEM for 24 h. Untreated differentiated 3T3-L1 adipocytes were used as a negative control. At the end of the treatment, the cells were washed thrice with 1x DPBS and total RNA was extracted from the cells using the RNeasy Mini Kit (Qiagen, Maryland, USA) according to the manufacturer’s instructions. RNA concentration was determined using a NanoDrop One/Onec Microvolume UV-vis Spectrophotometer (Thermo Scientific, Schwerte, Germany) and Qubit™ RNA High Sensitivity (HS) and Broad Range (BR) Assay Kit (Life Technologies, Carlsbad, CA, USA). Complementary DNA (cDNA) was synthesized using the RT2 First Strand kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. The cDNA was amplified using RT2 SYBR® Green qPCR Mastermix (Qiagen) on a ready to use Mouse Adipogenesis RT2 Profiler PCR Array (PAMM-049ZA; Qiagen) to evaluate expression pattern of genes encoding pro/anti-adipogenic, pro/anti-white adipose tissue (WAT) and pro/anti-brown adipose tissue (BAT) transduction pathways. PCR analysis was conducted on the QuantStudio™ 3 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) at the SAMRC Primate Unit and Delft Animal Centre (Delft, Western Cape, South Africa) and data analysis using online GeneGlobe Data Analysis Centre (Qiagen, Germany) [25] . Analysis of qPCR data CT values obtained from qPCR experiments were exported and processed using the GeneGlobe online platform (http://www.qiagen.com/geneglobe). CT values from control and treatment groups were normalized against four housekeeping genes: beta-actin (ACTβ), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta-glucuronidase (GUSβ), and heat shock protein 90 alpha family class β member 1 (HSP90AB1). The stability of the four reference genes was evaluated using the RefFinder algorithm, which integrates geNorm, NormFinder, BestKeeper, and comparative Delta-Ct approaches. Relative gene expression was calculated using the 2−ΔΔCt method. Ct values exceeding 35 were excluded, as they were considered below the detection threshold. Gene expression results were expressed as fold change relative to the control group. Genes with a fold change ≥ 1.5 were considered differentially expressed, and statistical significance was determined at p ≤ 0.05. Functional enrichment analysis of DEGs Gene enrichment analysis was performed to identify the biological pathways and functions associated with the DEGs in differentiated 3T3-L1 adipocytes treated with cAuNPs. The analysis was conducted using the ShinyGO v8.0 computational tool. The upregulated (n = 18) and downregulated (n = 17) DEGs were used as input for enrichment analysis. The DEGs were analysed for over-representation in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, as well as in the three Gene Ontology (GO) categories: Biological Process (BP), Cellular Component (CC), and Molecular Function (MF). Enrichment analysis in ShinyGO was performed with the default parameters, including a false discovery rate (FDR) correction for multiple testing to ensure statistical significance. The analysis generated a list of enriched GO terms and KEGG pathways, which provided insights into the functional roles and biological processes associated with the upregulated and downregulated DEGs following treatment with cAuNPs. Enriched terms with an adjusted p-value of <=0.05 were considered statistically significant. The results were visualized as enrichment plots and bar graphs to illustrate the most significantly enriched pathways and GO terms in both gene sets, thereby elucidating the molecular mechanisms underlying the cellular response to cAuNPs in differentiated 3T3-L1 adipocytes. Protein-protein interaction (PPi) network analysis of DEGs STRING module in Cytoscape was used to investigate the PPi and identify key hub genes among DEGs in differentiated 3T3-L1 adipocytes treated with cAuNPs. The gene lists were analyzed separate for upregulated (n = 18) and downregulated (n = 17) DEGs. The gene symbols were uploaded into the STRING module within Cytoscape (v. 3.10.2), and a PPi network was constructed based on a confidence score of ≥ 0.4. The interaction networks were visualized to identify functional connections among the DEGs, revealing direct and indirect relationships based on known and predicted interactions. Subsequently, the hub genes for upregulated and downregulated DEGs were identified using the CytoHubba plugin in Cytoscape. The gene lists were input into CytoHubba, and node scores were calculated using the degree method to determine the top five hub genes from both upregulated and downregulated gene sets. The degree method, which counts the number of connections each node has within the network, was chosen due to its ability to identify genes with the highest number of direct interactions, thus highlighting their centrality and potential biological significance in the context of cAuNPs treatment. Statistical analysis The data are expressed as the mean ± standard error of the mean (SEM) of three independent experiments. Cell viability (WST-1) assay and ORO staining comparisons were performed using two-way analysis of variance (ANOVA). Statistical analysis was performed using GraphPad Prism v 6.1 software (San Diego, CA, USA). Differences were considered to be statistically significant when the p-value was ≤ 0.05. Results and discussion Synthesis of AuNPs has attracted significant attention in various fields, particularly in biomedical applications. The unique physicochemical properties of AuNPs offer promising potential for the development of nanomedicine, that are target specific with sustainable effects [27]. Our group, has over the years, extensively investigated the potential of AuNPs-based therapies for combating obesity through in vitro [18, 28], in vivo, and ex vivo studies [18]. A study by Wusu et al. demonstrated that untargeted cAuNPs downregulated genes involved in lipid metabolism, particularly those associated with steatosis, phospholipidosis, cholestasis, and fatty acid metabolism [19]. These findings suggested potential anti-lipogenic and anti-obesity effects of cAuNPs, warranting further exploration of their effects on adipocytes. In the current study, we investigated the effects of cAuNPs on differentiated 3T3-L1 adipocytes to confirm and extend the understanding of their potential anti-obesity properties. Physicochemical properties of cAuNPs cAuNPs with an average core diameter of 14 nm were synthesized via the citrate-reduction method, producing particles with characteristic features consistent with previously reported studies [18, 22, 28]. The UV-vis absorption spectrum revealed maximum absorbance of the cAuNPs at 521 nm (Fig. 1a. The DLS measurements indicated a slightly higher average hydrodynamic diameter of 16.14 nm (Fig. 1b), reflecting the hydration layer formed by citrate and water molecules surrounding cAuNPs surface [29]. Citrate acted as both a reducing and stabilizing agent, capping the AuNPs surface to prevent aggregation and providing colloidal stability, which also influences cellular interactions and uptake. The cAuNPs had a good colloidal stability in aqueous solution with a zeta potential (ζ-potential) or surface charge of − 28.7 mV (Fig. 1c). HRTEM confirmed that the cAuNPs were spherical, with a core diameter of 14.20 nm (Fig. 1d, e). Physicochemical properties of the cAuNPs. a UV-vis spectrum, b hydrodynamic size from DLS, c Zeta potential, d HRTEM, and e core size distribution These physicochemical properties are critical, as they can significantly influence nanoparticle interactions with biological systems. The nanoscale size enables efficient cellular uptake while minimizing cytotoxicity and contributes to particle stability in both aqueous and biological environments. The negative surface charge reduces aggregation and enhances biocompatibility. Moreover, the uniform spherical morphology supports predictable cellular responses, which are essential for reliable in vitro studies [30]. Effects of cAuNPs on cell viability and proliferation The 3T3-L1 preadipocytes were fully differentiated into mature adipocytes at day 10 post-MDI induction, as evidenced by the presence of visible lipid droplets, confirming successful adipocyte differentiation (Fig. 2a). In contrast, undifferentiated 3T3-L1 cells maintained under the same conditions without MDI treatment showed no lipid droplets (Fig. 2b), ruling out auto-differentiation and validating the cell model. Differentiation of 3T3-L1 cells into adipocytes. a Differentiated cells following MDI induction showing intracellular lipid droplet accumulation; b undifferentiated cells maintained in DMEM lacking lipid droplets. Images were captured using an EVOS XL Core imaging system under identical imaging conditions for all groups at 10x magnification The effect of 14 nm cAuNPs on the viability of differentiated and undifferentiated 3T3-L1 cells was evaluated using the WST-1 assay. As shown in Fig. 3, the cAuNPs showed no significant differences between the control group and the evaluated doses at any of the tested time points. The cell proliferation rates at 48 h (Fig. 3b) and 72 h (Fig. 3c) showed a slight insignificant increase in the percentage of cell viability, especially for the undifferentiated cells, thus, indicating a noncytotoxic effect and biocompatibility of the cAuNPs on 3T3-L1 cells. These findings align with previous studies demonstrating the biocompatibility of AuNPs, where non-cytotoxic effects in fibroblast and adipocyte cell models exposed to similar-sized cAuNPs were reported [31–33]. Similarly, Yi et al. found that cAuNPs enhanced proliferation in mammalian cells without affecting viability [33]. Additionally, Thovhogi et al. [18] and Wusu et al. [19] observed that cAuNPs exhibited minimal cytotoxicity to colorectal cancer (Caco-2) cells at lower concentrations (≤ 12.5 nM). However, at higher concentrations, a decline in Caco-2 cell viability was noted suggesting a concentration-dependent response [19]. Effects of cAuNPs on differentiated and undifferentiated 3T3-L1 cell viability. 3T3-L1 cells were treated with 0 and 400 nM cAuNPs for a 24 h; b 48 h and c 72 h. Cell viability was assessed using WST-1 assay. Data are presented as the mean ± SEM of three independent experiments. No statistically significant differences were observed Reduction of lipid content in 3T3-L1 differentiated adipocytes The anti-adipogenic effect of cAuNPs was evaluated using ORO staining in the 3T3‐L1 cells at concentrations of 0–400 nM. Microscopic examination of ORO-stained cells showed no obvious visual differences in lipid droplet accumulation (Fig. 4a–c). However, quantitative analysis of the solubilized dye as shown in Fig. 5, cAuNPs treatment resulted in a concentration-dependent reduction of lipid accumulation in differentiated 3T3‐L1 adipocytes. The inhibitory effects of the treatment on adipogenesis were clear on the three timepoints, and was highest at 72 h, which showed statistical significance even at the lowest concentration of 25 nM. The capacity to achieve substantial lipid reduction at low concentrations emphasizes the efficacy of cAuNPs and their therapeutic potential in developing anti-obesity therapies. These findings were comparable with those of previous studies demonstrating the ability of cAuNPs to modulate lipid metabolism. Akter et al. [31] and Chen et al. [34] reported reductions in lipid accumulation in adipocytes treated with AuNPs at higher concentrations. In contrast, our study shows that lipid inhibition occurs at significantly lower doses (≤ 400 nM). Additionally, AuNPs suppressed adipogenesis by modulating oxidative stress and gene expression, these mechanisms may contribute to the lipid-reducing effects observed in this study [33, 35]. Effect of cAuNPs on the lipid content of 3T3-L1 differentiated cells stained by ORO dye. a Undifferentiated 3T3-L1 preadipocytes, b differentiated 3T3-L1 adipocytes. Red colour represents lipid droplets representing intracellular lipid content. Images were captured using an EVOS XL Core imaging system under identical imaging conditions at 40x magnification Effect of cAuNPs on lipid content of 3T3-L1 cells stained by ORO dye quantitative representation. a 24 h. b 48 h. c 72 h. Data are expressed as mean ± S.E.M., (n = 3). ****p < 0.0001, *p < 0.05 compared to untreated undifferentiated controls Effects of cAuNPs on gene expression levels of adipogenic genes The RT2 Profiler PCR array data revealed that a total of 35 out of 84 genes were differentially expressed in differentiated 3T3-L1 adipocytes treated with 12.5 nM of cAuNPs, with 18 genes upregulated and 17 genes downregulated (Table 1). Among which, the expression of 5 genes, Dlk1, Klf2, Runx1t1, Rxra, and VDR was downregulated in all genes and significantly altered compared to the other DEGs. Each of these genes play a role in adipocyte function and lipid metabolism. Dlk1 and Runx1t1 are typically involved in anti-adipogenic processes, where their downregulation specifically signals a reduction in adipogenesis, as both genes are inhibitors of early adipocyte differentiation (Sul, [36]). Dlk1 has a well-defined role in preventing premature fat cell development [37], while Runx1t1 restrains adipocyte differentiation [38]. By downregulating these genes, cAuNPs may help reduce the formation of new fat cells, which could be beneficial in controlling excessive lipid accumulation within tissues. This effect is particularly valuable in managing adipose tissue expansion and associated cellular processes. Table 1Up- and downregulated DEGs in differentiated 3T3-L1 adipocytes treated with cAuNPsGene DescriptionGene SymbolGene FunctionUpregulatedAdipogenin Adig AdipokinesAdiponectin, C1Q and collagen domain containing Adipoq Adipokines; PPARγ TargetsBone morphogenetic protein 2 Bmp2 Pro-WATcAMP responsive element binding protein 1 Crebp1 Pro-Brown Adipose TissueComplement factor D (adipsin) Cfd Adipokines; PPARγ TargetsFatty acid binding protein 4, adipocyte Fabp4 PPARγ Targets; Pro-AdipogenesisFibroblast growth factor 2 Fgf2 Pro-AdipogenesisKruppel-like factor 4 (gut) Klf4 Pro-WATNuclear receptor subfamily 0, group B, member 2 Nr0b2 Anti-Brown Adipose TissueNuclear receptor subfamily 1, group H, member 3 Nr1h3 Anti-Brown Adipose TissuePeroxisome proliferator activated receptor alpha Pparα Pro-Brown Adipose TissuePR domain containing 16 Prdm16 Pro-Brown Adipose TissueResistin Retn Adipokines; PPARγ TargetsSecreted frizzled-related protein 1 Sfrp1 Pro-AdipogenesisSecreted frizzled-related protein 5 Sfrp5 Pro-AdipogenesisSonic hedgehog Shh Anti-AdipogenesisUncoupling protein 1 (mitochondrial, proton carrier) Ucp1 Pro-Brown Adipose TissueWingless-related MMTV integration site 5B Wnt5b Pro-Adipogenesis Downregulated Adrenergic receptor, beta 2 Adrb2 Anti-AdipogenesisAngiotensinogen (serpin peptidase inhibitor, clade A, member 8) Agt Hormones; PPARγ TargetsCCAAT/enhancer binding protein (C/EBP), beta Cebpb Pro-AdipogenesisCCAAT/enhancer binding protein (C/EBP), delta Cebpd Pro-AdipogenesisDelta-like 1 homolog (Drosophila) Dlk1* Anti-AdipogenesisDickkopf homolog 1 (Xenopus laevis) Dkk1 Pro-AdipogenesisFibroblast growth factor 1 Fgf1 Pro-AdipogenesisGATA binding protein 3 Gata3 Anti-WATKruppel-like factor 2 (lung) Klf2* Anti-WATLamin A Lmna Pro-AdipogenesisLeptin Lep AdipokinesNuclear receptor co-repressor 2 Ncor2 Anti-AdipogenesisRetinoid X receptor alpha Rxra* Pro-AdipogenesisRunt-related transcription factor 1; translocated to, 1 (cyclin D-related) Runx1t1* Anti-AdipogenesisTranscription factor 7-like 2, T-cell specific, HMG-box Tcf7l2 Anti-AdipogenesisVitamin D receptor VDR* Anti-AdipogenesisWingless related MMTV integration site 10b Wnt10b Anti-Brown Adipose Tissue*Statistically significant at p ≤ 0.05 Up- and downregulated DEGs in differentiated 3T3-L1 adipocytes treated with cAuNPs *Statistically significant at p ≤ 0.05 Similarly, Rxra and Vdr play pivotal roles in regulating lipid metabolism within adipocytes. Rxra encodes a receptor that mediates retinoid and fatty acid signalling, essential for lipid storage and mobilization [39], while Vdr, the gene for the vitamin D receptor, affects both adipocyte differentiation and lipid accumulation [40]. The observed downregulation of these genes by cAuNPs suggested that the nanoparticles may be actively reducing the adipocyte’s capacity for lipid storage, aligning with a broader metabolic shift towards lipid mobilization rather than retention. Meanwhile, Klf2, recognized for its anti-WAT effects, was also downregulated, implying that its suppression could encourage pathways that promote energy expenditure [41]. WAT, the primary site of fat storage, contrasts with BAT, which is involved in thermogenesis and energy dissipation [42]. By downregulating Klf2, cAuNPs may foster an environment where adipocytes shift towards a more energy-dissipative state, supporting a metabolic profile that favours energy usage over storage. In addition to the downregulated genes that showed statistically significant changes, several upregulated genes (Adig, Adipoq, Fabp4, Prdm16, Ucp1, Bmp2, and Klf4), despite not reaching significance, displayed expression patterns that may have biological relevance in adipocyte function and metabolism. Each of these genes play a role in adipocyte differentiation, lipid metabolism, or thermogenic regulation. Adipoq encodes adiponectin, a key adipokine involved in insulin sensitivity and lipid homeostasis [43], while Fabp4 mediates fatty acid transport and is a downstream target of PPARγ [44], linking it to lipid storage. Prdm16 and Ucp1 are canonical regulators of BAT [45], promoting energy expenditure, whereas Bmp2 and Klf4 support adipocyte differentiation and maturation [46]. The concurrent upregulation of these genes may reflect coordinated modulation of adipogenic and energy-dissipating pathways, complementing the downregulation of anti-adipogenic and lipid storage genes. Together, these patterns suggest that cAuNPs may favour a metabolic shift toward energy mobilization and thermogenic potential in 3T3-L1 adipocytes. Analysis of KEGG pathways in the DEGs Functional enrichment analysis was performed to elucidate the biological significance of the DEGs in differentiated 3T3-L1 adipocytes treated with cAuNPs. The analysis was conducted separately for upregulated (n = 18) and downregulated (n = 17) genes using ShinyGO v8.0, and revealed significant enrichment in several key pathways and biological processes as shown in Figs. 6 and 7. KEGG pathway enrichment analysis provided insights into the pathways that may mediate the biological response to cAuNPs in differentiated 3T3-L1 adipocytes. Among the 18 upregulated genes, the top three KEGG pathways enriched by fold enrichment were the PPAR signalling pathway, Basal cell carcinoma, and signalling pathways regulating pluripotency of stem cells (Fig. 4a). Notably, the PPAR signalling pathway plays a critical role in regulating lipid metabolism, adipogenesis, and energy homeostasis. Activation of PPAR signalling pathway suggested that cAuNPs treatment may enhance lipid metabolism. The enrichment of pathways associated with cell pluripotency may also point to the potential for regenerative effects in adipose tissues. Functional Enrichment Analysis of upregulated genes in cAuNP-treated 3T3-L1 adipocytes. a Enriched KEGG pathways. b Gene Ontology Biological process (BP) terms. c Gene Ontology Cellular Component (CC) terms. d Gene Ontology Molecular Functions (MF) terms Functional Enrichment Analysis of downregulated genes in cAuNP-treated 3T3-L1 adipocytes. a Enriched KEGG pathways. b Gene Ontology Biological process (BP) terms. c Gene Ontology Cellular Component (CC) terms. d Gene Ontology Molecular Functions (MF) terms Additionally, the KEGG pathway analysis of the 17 downregulated genes indicated that a significant number of DEGs are involved in pathways associated with cancer, with the top three pathways enriched being Thyroid cancer, Basal cell carcinoma, and Acute myeloid leukaemia (Fig. 5a). The presence of cancer-related pathways suggested that cAuNPs treatment may exert anti-tumorigenic effects, particularly by suppressing genes involved in uncontrolled cell proliferation. This is of particular interest given the link between obesity and increased cancer risk, indicating that cAuNPs may influence both metabolic and cancer-related pathways. Furthermore, research has shown that hyperplastic adipogenesis shares certain mechanisms with oncogenic pathways, suggesting that cAuNPs might exhibit effects that extend beyond traditional lipid metabolism. Analysis of gene ontology in the DEGs In addition to KEGG pathway analysis, GO enrichment analysis of both upregulated and downregulated genes provided further insights into the BP, CC and MF affected by cAuNPs treatment (Fig. 6). GO enrichment analysis for the upregulated genes revealed significant over-representation of 15 BP terms, including brown fat cell differentiation, fat cell differentiation, and positive regulation of Wnt signalling pathway (Fig. 6a). The upregulation of brown fat cell differentiation is particularly important, as BAT is involved in energy expenditure and thermogenesis, thereby promoting fat burning. In addition, the positive regulation of the Wnt signalling pathway is relevant for its role in controlling adipogenesis and glucose metabolism. These findings suggested that cAuNPs may positively influence adipocyte differentiation and metabolic regulation, offering potential anti-obesity effects. The analysis also identified enrichment in 9 CC terms (Fig. 4b) and 15 MF terms (Fig. 6c). For the downregulated genes, 12 BP terms were enriched, including fat cell differentiation, positive regulation of developmental processes, and negative regulation of transcription DNA-templated (Fig. 7b). The suppression of fat cell differentiation and transcriptional regulation may reflect a protective mechanism against excessive adipogenesis and unregulated fat accumulation. In addition, 15 CC terms (Fig. 6c) and 14 MF terms (Fig. 7d) were enriched, indicating the involvement of these genes in diverse cellular functions. Protein interaction network analysis of DEGs The PPi analysis revealed complex interaction networks among the DEGs in differentiated 3T3-L1 adipocytes treated with cAuNPs (Fig. 8). For the upregulated genes, key nodes within the network demonstrated high connectivity, indicating their central role in adipogenic and adipokine-related processes (Fig. 8a). The hub gene analysis identified Adipoq, Retn, Fabp4, Fgf2, and Bmp2 as the top five hub genes among the upregulated DEGs, ranked in order of their connectivity (Fig. 8b). These genes are involved in adipokine production, adipogenesis, and the differentiation of adipose tissues, suggesting a role in the response of adipocytes to cAuNPs. PPi network analysis of DEGs in cAuNPs-treated 3T3-L1 adipocytes. a PPi network of upregulated genes. b Hub gene analysis of upregulated genes. c PPi network of downregulated genes. d Hub gene analysis of downregulated genes For the downregulated DEGs, the hub gene analysis highlighted Cebpb, Rxra, Lep, Ncor2, and Cebpd as the top five genes (Figs. 8c and 8d). These genes are primarily associated with adipogenesis, adipokine signalling, and nuclear receptor activity, indicating their potential role in the suppression of adipogenic pathways in response to cAuNPs. Together, these findings suggested that cAuNPs may modulate both pro- and anti-adipogenic gene expression in differentiated adipocytes, affecting key regulatory pathways involved in adipose tissue metabolism and function. The observed anti-adipogenic effects of cAuNPs are likely mediated through modulation of key transcription factors and adipogenic genes. Downregulation of Cebpb and Cebpd, which are early regulators of PPARγ and C/EBPα, suggests that cAuNPs inhibit adipogenesis at an upstream level. Despite upregulation of Fabp4, the overall reduction in lipid accumulation indicates disruption of lipid storage processes, potentially through PPAR signalling and energy-dissipating pathways. Downregulation of Rxra and Vdr further highlights interference with the adipogenic network, supporting a shift towards decreased adipocyte differentiation and lipid accumulation. These results are consistent with previous reports showing that AuNPs can inhibit adipogenesis by targeting PPARγ and C/EBPα pathways [32, 35]. Several studies have demonstrated the anti-obesity effects of AuNPs in both in vitro and in vivo models. Akter et al. reported that AuNPs reduced lipid accumulation in adipocytes by modulating key metabolic pathways [31], while Ansari et al. found that AuNPs inhibited adipogenesis through the downregulation of PPAR-γ and C/EBP-α [35]. Chen et al. demonstrated that AuNPs enhanced mitochondrial activity and promoted lipolysis, leading to a reduction in adipose tissue mass [34]. Gao et al. observed improvements in glucose metabolism and insulin sensitivity in a high-fat diet-induced obesity model [47]. Functionalized AuNPs were also shown to suppress lipid accumulation in both HepG2 and 3T3-L1 cells [33], highlighting their potential in obesity management. Furthermore, Simu et al. found that PEGylated AuNPs inhibited adipocyte differentiation by activating the AMPK signalling pathway [32], while Li et al. demonstrated significant reductions in body weight and fat mass in obese rats following AuNP treatment [48]. These findings suggest that AuNPs could serve as promising therapeutic agents for obesity by inhibiting adipogenesis, promoting lipolysis, and improving metabolic function. Conclusion In this study, 14 nm cAuNPs demonstrated low to no cytotoxic effects on both differentiated and undifferentiated 3T3-L1 cells, suggesting that the cAuNPs are biocompatible. Quantitative assays demonstrated that cAuNPs reduced lipid accumulation in a concentration dependent manner, supporting their anti-adipogenic effects. Gene expression analysis revealed regulation of key genes involved in lipid metabolism and adipogenesis, providing insights into the molecular mechanisms underlying these effects. Pathway enrichment analyses, including KEGG and GO, indicated that cAuNPs activate lipid metabolism pathways and promote thermogenesis while downregulating genes involved in adipogenesis. These changes in gene expression suggested that cAuNPs may support a shift towards an energy-expending cell phenotype, indicating potential anti-obesity effects. Collectively, these findings suggest that cAuNPs have therapeutic potential in metabolic health management, particularly in reducing lipid accumulation in adipose tissue. Notably, the anti-obesity effects of AuNPs have been demonstrated in vivo, as significant improvements in body composition in a rat model of diet-induced obesity were reported. Nevertheless, further research is necessary to evaluate the effects of cAuNPs in in vivo models, optimize AuNPs formulation for clinical use, and investigate long-term safety to fully understand their potential in therapeutic applications for the management and treatment of obesity and obesity-related diseases. Acknowledgements The manuscript is part of the MSc thesis by Mrs A Hyera, full thesis is available online “https://hdl.handle.net/10566/13383”, the University of the Western Cape Library Sciences has granted permission to publish. Author contributions AH - Investigation, Formal analysis, Writing - original draft preparation, project administration; JRS - Methodology, Formal analysis, Supervision, Resources, Writing-review and editing; AOF -Methodology, Formal analysis, Writing-review and editing; KBG -Methodology, Formal analysis, Writing-review and editing; ZM - Investigation, Formal analysis, Writing-review and editing; AMM - Conceptualization, Methodology, Resources, Writing-review and editing; MM - Conceptualization, Methodology, Resources, Writing-review and editing; NRSS - Conceptualization, Methodology, Formal analysis, Supervision, Resources, Writing-review and editing. All authors have read and agreed to the published version of the manuscript. Funding The study was funded by UWC Nanotechnology Platform and the DSTI Master of Science in Nanoscience Programme. Data availability The microarray datasets generated and analyzed during the current study are available in the NCBI Gene Expression Omnibus repository, available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE310135, accession number: GSE310135. Declarations Ethics approval and consent to participate Not applicable. Clinical trial number Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Jyoti Rajan Sharma, Email: Jyoti.Sharma@mrc.ac.za. Nicole Remaliah Samantha Sibuyi, Email: nsibuyi@uwc.ac.za. References Associated Data Data Availability Statement The microarray datasets generated and analyzed during the current study are available in the NCBI Gene Expression Omnibus repository, available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE310135, accession number: GSE310135.